Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Capital Expenditures: 2020-2025

Historic Capital Expenditures for Cellebrite DI (CLBT) over the last 5 years, with Sep 2025 value amounting to -$3.3 million.

  • Cellebrite DI's Capital Expenditures fell 82.53% to -$3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.4 million, marking a year-over-year decrease of 62.75%. This contributed to the annual value of $8.6 million for FY2024, which is 63.75% up from last year.
  • Per Cellebrite DI's latest filing, its Capital Expenditures stood at -$3.3 million for Q3 2025, which was up 7.93% from -$3.6 million recorded in Q2 2025.
  • Over the past 5 years, Cellebrite DI's Capital Expenditures peaked at -$778,000 during Q4 2021, and registered a low of -$3.6 million during Q2 2025.
  • Its 3-year average for Capital Expenditures is -$2.1 million, with a median of -$2.1 million in 2024.
  • Its Capital Expenditures has fluctuated over the past 5 years, first skyrocketed by 53.84% in 2023, then plummeted by 151.27% in 2024.
  • Quarterly analysis of 5 years shows Cellebrite DI's Capital Expenditures stood at -$778,000 in 2021, then tumbled by 78.79% to -$1.4 million in 2022, then slumped by 62.47% to -$2.3 million in 2023, then plummeted by 40.62% to -$3.2 million in 2024, then crashed by 82.53% to -$3.3 million in 2025.
  • Its Capital Expenditures stands at -$3.3 million for Q3 2025, versus -$3.6 million for Q2 2025 and -$2.3 million for Q1 2025.